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1. Introduction
  Pneumocystis carinii (P. carinii) pneumonia (PCP), caused 
by P. carinii, remains an important cause of morbidity 
and mortality in immunocompromised hosts[1]. Although 
many therapeutic options are used for the treatment of 
Pneumocystis pneumonia, there are adverse side effects, 
toxicity and resistance in those treatments[2,3]. The 
development of immunotherapetic modalities such as 
active immunization or passive immunotherapy play an 
increasing important role in the prevention and treatment 
of infection. Immunization of BALB/c mice with intact P. 
carinii cells provides protection against PCP[4-6]. Since P. 
carinii cannot be satisfactorily cultivated, development 
of a subunit vaccine is essential. However, there are no 
convincing data showing that a protective immune response 
has been elicited after active immunization with an 
isolated antigen of P. carinii[7]. Although DNA vaccination 
has been used for other P. carinii antigen, completely 
protection against P. carinii has not been reported[8]. 
In our DNA vaccination studies, we focused on the p55 
antigen of rat-derived P. carinii. It has been reported that 
purified p55 protein can afford partial protection against 
the subsequent development of P. carinii pneumonia in 
some animal models. A study has shown that the 5’ portion 
of the molecule, p55 (1-200), appears immunologically 
silent, failing to elicit lymphocyte proliferation or cytokine 
secretion[9]. The 3’ portion of p55 (268-414), which causes 
the release of IL-1 and TNF-毩 in spleen cell suspensions 
from animals with environmental exposure to P. carinii, 
has at least one immunodominant region. In this study, we 
tested the efficacy of DNA immunization with p55-582 in 
eliciting protective immunity of BALB/c mice against P. 
carinii. 
2. Materials and methods
2.1. Amplification and cloning of the target gene fragment 
  Dexamethasone sodium phosphate (4 mg per week, 
Jinling, Nanjing, China) was given subcutaneously twice 
per week to immunosuppress the female Sprague-Dawley 
rats. Housing and all procedures involving animals 
were performed according to the guidelines of animal 
welfare in Nantong University. The total genomic DNA 
was isolated from homogenized P. carinii-infected lung 
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tissues of rats and used to perform polymerase chain 
reaction (PCR). The specific primers (sense primer: 5’- 
CCGGAATTCACCATGGATTTATGTTGT -3’ and antisense 
primer: 5’- CCGCTCGAGTCAATGCGTATTATCTG -3’) were 
synthesized for amplification of a 582 bp DNA fragment of 
p55 gene. The PCR products were named after p55-582.
  This coding sequence was cloned into pGEM-T vector 
(Promega, Madison, USA). The insert sequence in plasmid 
was verified by DNA sequencing. The DNA fragment was 
subcloned into pcDNA3.1(+) at the EcoRⅠand XhoⅠsites 
for DNA vaccination. To generate recombinant p55/582 
protein, the coding sequence was subcloned into the 
EcoRⅠand XHoⅠsites of a pGEX-4T-1 (Pharmacia, 
Peapack, NJ). Escherichia coli BL21 transformed with the 
plasmid pGEX-4T-p55-582 was grown at 22 曟 for 6 h in 
the presence of 0.4 mM isopropy-毬-D- thiogalactoside 
(IPTG) prior to purification of glutathione-agarose (Sigma, St. 
Louis, MO, USA) under denaturing conditions.
2.2. Expression of p55-580 protein in COS-7 cells
 
  C O S - 7  c e l l s  w e r e  m a i n t a i n e d  i n  R P M I  1 6 4 0 
mediumsupplemented with 10% fetal bovine serum. When 
75% confluency was obtained, cells were transfected with 
0.1 毺g of the appropriate plasmid DNA with Lipofectamine 
(Invitrogen, Shanghai, China) and Opti-MEM reduced-
serum medium (Invitrogen, Shanghai, China). The 
supernatants were separated by SDS-PAGE. The expression 
of p55-582 in serum was detected by western bloting.
2.3. Immunization and challenge
 
  Mice (10 per group) were immunized with 100 毺g purified 
pcDNA3.1(+)-p55-582, pcDNA3.1(+) and PBS, respectively. 
Mice in each vaccination group were immunized four times 
at 2-week intervals by subcutaneous or peritoneal injection. 
Animal care and experimental procedures were approved 
by the Animal Ethics Committee of Nantong University. 
Blood was collected from mice at day 0, day 14, day 28, 
day 42, day 56, and allowed to clot. The mice were injected 
with dexamethasone sodium phosphate, which was given 
subcutaneously twice per week to immunosuppress the 
animals at day 56. At day 70, SD rats with ether anesthesia, 
were challenged with 0.2 mL P. carinii suspension through 
the trachea. Then rats continued injection of dexamethasone 
in two weeks. All the SD rats were killed at 84 days, and the 
lung tissues were extracted.
2.4. Evaluation
  To assess parasite-specific antibody titers, wells were 
coated with purified antigen GST-p55/582(1.25 毺g/mL). 
Plates were then blocked with 200 毺L of 1% bovine serum 
albumin(Sigma, St. Louis, MO, USA)solution overnight at 4 ℃.
Serum samples were diluted at 1:80 in blocking solution 
and 100 毺L were reacted for 1 h at 37 ℃. Next, wells were 
incubated with 100 毺L of a horseradish peroxidase (HRP) 
-conjugated goat anti-mouse IgG(Sigma, St. Louis, MO, USA)
for 1 h at 37 ℃ in a moist chamber. The plate was developed 
with 100 毺L of peroxidase substrate for 5 minutes. The 
plates were read by ELISA microtiter plate reader at 490 Å 
and optical density (OD) was determined. 
  Single cell suspensions were prepared at day 56 (two weeks 
after the fourth immunization). Splenocytes were co-cultured 
with ConA (10 毺g/mL, sigma) in RPMI-1640 for 58 hours 
before addition of MTT (10 毺L per well), and incubated at 
37 ℃ for 4 h. For each pellet, 100 毺L of dimethylsulfoxide 
(DMSO) was added to dissolve the formazan for 10 minutes. 
Absorbance was measured by ELISA plate reader with a test 
wavelength of 570 nm and a reference wavelength of 630 nm 
to obtain sample signals. 
2.5. RT-PCR analysis
 
  The P. carinii  burden was determined by real-
time PCR quantification of the single-copy DHFR 
gene as described previously[10]. The specific primers 
( 5 ’ - T A G A T C C A G A G A T T C A T T T C G A G - 3 ’ )  a n d  ( 5 ’ - 
GTTGCACTTACAACTTCTTATGG-3’) were designed to 
amplify a 234-bp fragment of the single-copy DHFR gene 
(AF322061). Duplicate reactions were performed using SYBR 
Premix Ex TaqTM(TaKaRa Biotechnology, Dalian,China) 
with 0.2 毺M of each primer and 2 毺L of cDNA. Primers 
for β-Actin (5’-CCCATCTATGAGGGTTACGC-3’ , 5’-
TTTAATGACACGCACGATTTC-3’) were designed using 
Primer5.0 Software. Cycling conditions were: 15 s at 93 ℃ 
followed by 40 cycles of 95 ℃ for 5 s, 60 ℃ for 15 s and 
72 ℃ for 20 s. Melt curve analysis and 2% agarose gel 
electrophoresis of the amplicon were used to determine 
specificity of the amplicon. Data was normalized with 毬
-actin and results were expressed as fold amplification 
compared with normal and uninfected mice. 
2.6. Statistical analysis
  Data are presented as the means依standard deviations and 
were considered significant at P﹤0.05. Data were evaluated 
for statistical significance by one-way analysis of variance.
3. Results
3.1. Construction of pcDNA3.1(+)-p55-582
  To evaluate immunogenicity of p55/582 protein，we 
amplified a 582-bp DNA fragment from P. carinii genomic 
DNA[11] and constructed a recombinant plasmid named 
pcDNA3.1(+)-p55-582. The insert fragment was confirmed 
by restriction enzyme digestion and DNA sequence analysis. 
Figure 1 showed that the length of the available products by 
the double-digested with EcoR I and Xho I endonucleases 
was identical to the length of the PCR products. All the 
data reveals that the recombinant eukaryotic plasmid 
pcDNA3.1(+)-p55-582 has been constructed successfully.
231 130 bp
9 416 bp
6 557 bp
4 361 bp
2 322 bp
2 027 bp
M1                 1                 2                  3                 4                M2
Figure 1. Characterization of the recombinant plasmid pcDNA3.1(+)-
p55-582 by restriction enzyme digestion. 
M1:-Marker 毸- Hind Ⅲ digest; M2:Marker DL2000; Lane 1: 
pcDNA3.1(+)-p55-582 plasmid; Lane 2: pcDNA3.1(+) plasmid; Lane 
3: pcDNA3.1(+)-p55-582 plasmid digested with EcoR I and Xho I; 
Lane 4: 582 bp DNA fragment of p55 gene.
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3.2. Expression of p55-582 in COS-7
 The ability of the recombinant DNA plasmids to express 
their antigens was evaluated in COS-7 transfected cells. 
Cells transfected with pcDNA3.1(+)-p55-582 showed 
positive, while cells transfected with pcDNA3.1(+) were 
negative. As shown in Figure 2, a band with a molecular 
weight of 21 kDa,which corresponds to the expected 
molecular weight of the p55-582 protein, was detected in 
cell lysates by western blotting. 
1                       2
21 kDa
37 kDa
P55-582
GAPDH
Figure 2. Analysis of p55-582 protein expression by western blotting. 
COS-7 cells were transfected with pcDNA3.1 (Lane 1) and 
pcDNA3.1(+)-p55-582 (lane 2). Anti-GAPDH was used as a control.
 
3.3. Strong immune response of BALB/c mice immunized with 
pcDNA3.1(+)-p55-582
  The ability of immunization to elicit humoral and cell 
mediated immune responses to pcDNA3.1(+)-p55-582 were 
evaluated by ELISA and lymphocyte proliferation assay. 
Serum antibodies against by ELISA showed a significant 
increase over control animals immunized with pcDNA3.1(+) 
or PBS alone at all time points (Figure 3). Antibody levels 
were at peak after the fourth immunization in animals. 
Antibodies to p55-582 were detected in animals immunized 
with pcDNA3.1(+)-p55-582 at two week after the first 
immunization (day 14) and these persisted throughout the 
period of immunization. Antibody levels were significantly 
higher than antibodies detected in animals immunized 
with pcDNA3.1(+) (P＜0.05). Spleens were isolated to 
determine cellular immune responses to p55-582 protein. 
The proliferation responses to p55-582 protein were 
significantly greater in splenocytes from pcDNA3.1(+)-p55-
582 immunized mice than in those from control mice (P﹤
0.05)(data not shown). 
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Figure 3. ELISA analysis of antiboby responses to pcDNA3.1(+)-
p55-582 antigen. 
Significant differences(P﹤0.05) existed from values for control 
group[pcDNA3.1(+)and PBS group] on day 14, day 28, day 42, day 
56, respectively, as calculated by the means - standard deviations.
3.4. Challenge of immunized mice
  pcDNA3.1(+)-p55-582 vaccine candidates were evaluated 
for their ability to induce protective immunity against lethal 
challenge of P. carinii by real-time PCR quantification of 
the single-copy DHFR gene. As shown in Figure 4, reduction 
in organism burden was greater in animals immunized with 
pcDNA3.1(+)-p55-582 (0.124依0.092) versus the animals 
immunized with pcDNA3.1(+) (1.297依0.500) (P﹤0.05). It 
showed that immunization with p55-582 protein may induce 
protection against P. carinii challenge, compared to that 
observed in pcDNA3.1(+) inoculated mice. 
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Figure 4. The P. carinii burden measured by RT-PCR.
Significant differences (P﹤0.05) existed from values for control 
group[pcDNA3.1(+)and PBS group] on day 14, day 28, day 42, day 56, 
respectively, as calculated by the means - standard deviations. 
4. Discussion
  Pneumocystis is a common fungal opportunistic pulmonary 
pathogen of compromised hosts. Although many therapeutic 
options are available for the therapy of Pneumocystis 
pneumonia, the treatment is often complicated by side 
effects, toxicity, and markers of drug resistance[2,3]. Although 
previous studies have examined the host immune response 
to P. carinii, most have examined the response to specific P. 
carinii antigens because of the difficulty in vitro culture of P. 
carinii. Earlier studies characterizing the immune response 
to MSG demonstrated that it does elicit a T-cell response in 
rats and SCID mice[12,13]. However, evidence shows that MSG 
belongs to a family of genes and one or numerous species of 
MSG may be represented[14-17] by purifying native antigen. In 
our previous study, we cloned the full-length Pneumocystis 
kexin gene and found this protein can induce immune 
defense against P. carinii infection[18]. The availability of 
a recombinant antigen has permitted studies focusing on 
the cellular and humoral responses to a single antigen of 
P. carinii, p55. Several laboratories have shown that p55 is 
capable of eliciting cellular and humoral immune responses 
in animals naturally infected with P. carinii[11,19]. Compared 
with the whole extracts of P. carinii or the major surface 
antigen, MSG, the immunization with the entire p55 molecule 
is necessary in protection against subsequent P. carinii 
infection. Hence, this antigen moiety will likely be most 
useful as a vaccine candidate in combination with other 
immunogens which provide similar partial protection.
  Several studies about the immune response to p55 have 
shown that similar or improved levels of protection were 
afforded by an carboxyl terminus fragment of p55 containing 
amino acid residues 268-414, which contains a 10 tandem 
repeats of a glutamic acid-rich 7-aminoacid motif, 
compared to either the full molecule or a amino terminal 
fragment containing residues 1-200[2,9]. A synthetic peptide 
containing two copies of this repeat did stimulate a specific 
T-cell response, indicating that this region is a T-cell 
epitope present in the protein[2]. 
  Although P. carinii pneumonia occurs predominantly 
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in situations of T-cell dysfunction in humans and animal 
models, several studies have demonstrated the importance 
of antibodies in the host response to P. carinii. Antibodies 
do not appear to have a direct lethal effect on P. carinii, 
but may be likely to function as enhancers of macrophage 
phagocytosis[20,21]. In the model system used in the 
present study, antibodies was detected after 2 weeks of 
immunization with the pcDNA3.1(+)-p55-582. Significantly 
higher antibody titers against p55-582 were demonstrated 
among animals immunized with pcDNA3.1(+)-p55-582 
compared with control animals. We have further expanded 
these studies to the immunogenicity of the p55-582 by 
western blot. The recombinant protein, p55-582, can be well 
recognized by the animal immunized with pcDNA3.1(+)-
p55-582, while it can not response to the serum from the 
animal immunized with pcDNA3.1(+), indicating that p55-
582 protein has at least one immunodominant region. In 
the present study, we have demonstrated a lymphocyte 
proliferative in vitro from BALB/c mice immunized with 
the pcDNA3.1(+)-p55-582. Compared to control animals 
immunized with the pcDNA3.1(+)or PBS, pcDNA3.1(+)-p55-
582 did elicit a vigorous proliferative response in splenocytes 
from the immunized animals(P＜0.05). It reveals that the 
p55-582 protein is capable of eliciting cellular immune 
responses in immunized animals.
  The efficacy of this model in this study has largely been 
assessed based on reduction of organism burden by real-
time PCR other than lower lung weight to body weight 
ratio. Studies have shown that molecular methods for the 
detection of P. carinii can offer objectivity as well as the 
potential for increased sensitivity and specificity compared 
with lower lung weight to body weight ratio[22]. One of the 
main advantages of real-time PCR is that amplification and 
detection are performed in a closed system, reducing the 
possibility of run-to-run contamination. In addition, real-
time PCR assays have rapid turnaround times and present 
a level of objectivity that the current staining methods 
do not offer. In our study, organism burden by real-time 
PCR showed greatest reduction in pcDNA3.1(+)-p55-
582 immunized animals (P﹤0.05 compared to controls), 
indicating that p55-582 protein can offer partial protection 
against P. carinii.
  A detailed understanding of the host-parasite interaction 
will facilitate the development of immunoprophylaxis and 
immunotherapy for P. carinii infection. pcDNA3.1(+)-p55-
582, as a candidate DNA vaccine, can lead to strong cellular 
immunity, humoral immunity and reduce the organism 
burden in mice. Additional studies are needed to identify 
the mechanism of protection and optimize the level of 
protection afforded by p55-582 protein in the loss of CD4+ T 
cells predisposes mice. 
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